ArticleCommunications biology2020
Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6.
Article in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Identification of UBE2T as a novel diagnostic biomarker of psoriasis and proliferating UBE2T+ Keratinocyte in psoriasis.Journal of translational medicine · 2026Article
- A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.American journal of clinical and experimental immunology · 2026Review
- Immunotherapy-induced sialadenitis: sjögren's syndrome or a new sialadenitis.Frontiers in immunology · 2026Article
- Case Report: Rapid recurrence of psoriasiform dermatitis upon sequential anti-PD-1 therapy with pembrolizumab and tislelizumab with 3-year follow-up.Frontiers in immunology · 2026Article
- Clinical features, treatment, and outcomes of nivolumab induced psoriasis.Investigational new drugs · 2025Article
- PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.Science advances · 2025Article
- IL-6 and PD-1 antibody blockade combination therapy regulate inflammation and T lymphocyte apoptosis in murine model of sepsis.BMC immunology · 2025Article
- Elucidating Molecule-Crosstalk of Neutrophil Extracellular Traps Between Cardiovascular Disease and Psoriasis: Insights Into Mendelian Randomization, Single-Cell RNA Analysis, Shared Targets and the Role of Resveratrol.Journal of inflammation research · 2025Article
- Severe systemic cutaneous adverse reactions following camrelizumab therapy: a case report and literature review.Frontiers in immunology · 2025Review
- Psoriasis caused by camrelizumab in a patient with esophageal cancer: a case report.Frontiers in medicine · 2025Article
- Toripalimab induces exacerbation of psoriasis in an esophageal cancer patient: a case report.Frontiers in oncology · 2025Article
- Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.World journal of clinical cases · 2024Article
- Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy.Neurology · 2024Review
- Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis.Investigational new drugs · 2024Article
- Triggers for the onset and recurrence of psoriasis: a review and update.Cell communication and signaling : CCS · 2024Review
- Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.Frontiers in immunology · 2024Article
- Skin Infiltrate Composition as a Telling Measure of Responses to Checkpoint Inhibitors.JID innovations : skin science from molecules to population health · 2023Article
- Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.Journal of cancer research and clinical oncology · 2023Review
- Current landscape and tailored management of immune-related adverse events.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Use of immune checkpoint inhibitors that target programmed cell death-1 (PD-1) can lead to various autoimmune-related adverse events (irAEs) including psoriasis-like dermatitis. Our observations on human samples indicated enhanced epidermal infiltration of CD8 T cells, and the pathogenesis of which appears to be dependent on IL-6 in the PD-1 signal blockade-induced psoriasis-like dermatitis. By using a murine model of imiquimod-induced psoriasis-like dermatitis, we further demonstrated that PD-1 deficiency accelerates skin inflammation with activated cytotoxic CD8 T cells into the epidermis, which engage in pathogenic cross-talk with keratinocytes resulting in production of IL-6. Moreover, genetically modified mice lacking PD-1 expression only on CD8 T cells developed accelerated dermatitis, moreover, blockade of IL-6 signaling by anti-IL-6 receptor antibody could ameliorate the dermatitis. Collectively, PD-1 signal blockade-induced psoriasis-like dermatitis is mediated by PD-1 signaling on CD8 T cells, and furthermore, IL-6 is likely to be a therapeutic target for the dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.